Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Biogen Inc’s stock clocked out at $145.31, up 0.43% from its previous closing price of $144.69. In other words, the price has increased by $0.43 from its previous closing price. On the day, 1.28 million shares were traded. BIIB stock price reached its highest trading level at $146.88 during the session, while it also had its lowest trading level at $142.195.
Ratios:
To gain a deeper understanding of BIIB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.77. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 2.50. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Jefferies on September 25, 2025, initiated with a Buy rating and assigned the stock a target price of $190.
HSBC Securities Downgraded its Buy to Hold on April 28, 2025, while the target price for the stock was maintained at $118.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 02 ’25 when Singhal Priya sold 517 shares for $133.55 per share. The transaction valued at 69,045 led to the insider holds 5,772 shares of the business.
Singhal Priya bought 517 shares of BIIB for $69,045 on Sep 02 ’25. On Jul 08 ’25, another insider, Izzar Rachid, who serves as the Head of Global Product Strat. of the company, sold 2,223 shares for $135.00 each. As a result, the insider received 300,105 and left with 6,330 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 21304565760 and an Enterprise Value of 25140367360. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.90, and their Forward P/E ratio for the next fiscal year is 9.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.22 while its Price-to-Book (P/B) ratio in mrq is 1.21. Its current Enterprise Value per Revenue stands at 2.515 whereas that against EBITDA is 7.802.
Stock Price History:
The Beta on a monthly basis for BIIB is 0.09, which has changed by -0.23116404 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $194.13, while it has fallen to a 52-week low of $110.04. The 50-Day Moving Average of the stock is 3.26%, while the 200-Day Moving Average is calculated to be 7.36%.
Shares Statistics:
It appears that BIIB traded 1.60M shares on average per day over the past three months and 2007780 shares per day over the past ten days. A total of 146.60M shares are outstanding, with a floating share count of 146.34M. Insiders hold about 0.19% of the company’s shares, while institutions hold 89.84% stake in the company. Shares short for BIIB as of 1759190400 were 4880043 with a Short Ratio of 3.05, compared to 1756425600 on 4720975. Therefore, it implies a Short% of Shares Outstanding of 4880043 and a Short% of Float of 4.3.
Earnings Estimates
. The current market rating for Biogen Inc (BIIB) reflects the collective analysis of 25.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $3.45, with high estimates of $4.32 and low estimates of $2.83.
Analysts are recommending an EPS of between $16.1 and $13.92 for the fiscal current year, implying an average EPS of $15.71. EPS for the following year is $15.85, with 33.0 analysts recommending between $17.81 and $14.09.
Revenue Estimates
In . The current quarter, 24 analysts expect revenue to total $2.34B. It ranges from a high estimate of $2.49B to a low estimate of $2.26B. As of . The current estimate, Biogen Inc’s year-ago sales were $2.47BFor the next quarter, 24 analysts are estimating revenue of $2.27B. There is a high estimate of $2.44B for the next quarter, whereas the lowest estimate is $2.14B.
A total of 34 analysts have provided revenue estimates for BIIB’s current fiscal year. The highest revenue estimate was $10.03B, while the lowest revenue estimate was $9.09B, resulting in an average revenue estimate of $9.65B. In the same quarter a year ago, actual revenue was $9.68BBased on 34 analysts’ estimates, the company’s revenue will be $9.29B in the next fiscal year. The high estimate is $9.74B and the low estimate is $8.46B.
